NCT03962062View on ClinicalTrials.gov

A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

May 30, 2022

Study Completion Date

September 28, 2022

Conditions

Onchocerciasis

Interventions

DRUG

Moxidectin

2 mg tablets

Trial Locations (1)

Unknown

University of Health and Allied Services School of Public Health, Hohoe

All Listed Sponsors

lead

Medicines Development for Global Health

OTHER

NCT03962062 - A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years | Biotech Hunter | Biotech Hunter